Brilinta tablet: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(8 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Label template
{{Sandboxrx1}}
|authorTag={{JH}}
<div style="width: 80%">
|genericName=Brilinta
__NOTOC__
|drugClass=P2Y12 platelet inhibitor
{{CMG}} {{AE}} {{JH}}
|indication=Acute Coronary Syndromes (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction)
|hasBlackBoxWarning=Yes
|adverseReactions=A. BLEEDING RISK


* BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.
'''''For information about (Ticagrelor), click [[(Ticagrelor)|here]].'''''
* Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage.
* Do not start BRILINTA in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at least 5 days prior to any surgery.
* Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of BRILINTA.
* If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events.


B. ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
==Disclaimer==


Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. After any initial dose, use with aspirin 75-100 mg per day.
'''''WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature.  The information provided is not a medical advice or treatment.  WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer [[wikidoc:General_disclaimer|{{fontcolor|#FF0000|here}}]].'''''
==<span style="color:#FF0000; background:#000000;">Black Box Warning</span>==
 
{| style="border: 3px solid #696969;"
| style="background: #000000; border: 0px; padding: 20px 20px; width: 800px;" |
<center>
<font color="#F8F8FF" style="font-weight: bold;">WARNING: (A) BLEEDING RISK, and (B) ASPIRIN DOSE AND Brilinta EFFECTIVENESS</font>
</center>
 
<center>
<font color="#F8F8FF" size="1" style="font-style: italic;">See full prescribing information for complete boxed warning.</font>
</center>
 
<font color="#F8F8FF" style="font-weight: bold;">
''{{fontcolor|#FF0000|BLEEDING RISK:}}''
* Brilinta, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.
* Do not use Brilinta in patients with active pathological bleeding or a history of intracranial hemorrhage.
* Do not start Brilinta in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Brilinta at least 5 days prior to any surgery.
* Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgery.
* If possible, manage bleeding without discontinuing Brilinta. Stopping Brilinta increases the risk of subsequent cardiovascular events.
''{{fontcolor|#FF0000|ASPIRIN DOSE AND Brilinta EFFECTIVENESS:}}''
* Maintenance doses of aspirin above 100 mg reduce the effectiveness of Brilinta and should be avoided.
</font>
|}
 
==Overview==
 
{{PAGENAME}} is a [[P2Y12]] [[platelet]] inhibitor and [[platelet aggregation]] inhibitor drug that is FDA approved for the treatment of [[acute coronary syndromes|acute coronary syndromes (ACS)]] ([[unstable angina]], [[NSTEMI|non-ST elevation myocardial infarction]], or [[STEMI|ST elevation myocardial infarction]]). There is a Black Box Warning for this drug as shown <span style="background:#000000; font-weight: bold;">[[{{PAGENAME}}#Black Box Warning|{{fontcolor|#FF0000|here}}]]</span>. Common adverse reactions include _______.
 
==Adult Indications and Dosage==
 
===FDA-Labeled Indications and Dosage (Adult)===
 
====Acute Coronary Syndromes====
 
* Dosing Information
 
:: [[Brilinta tablet]] 180 mg tablet PO (two 90 mg tablets) loading dose and then continue treatment with 90 mg twice daily.
:: After the initial loading dose of aspirin (usually 325 mg), use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg.
:: ACS patients who have received a loading dose of clopidogrel may be started on BRILINTA.
:: BRILINTA can be administered with or without food.
:: A patient who misses a dose of BRILINTA should take one 90 mg tablet (their next dose) at its scheduled time.
 
 
===Off-Label Use and Dosage (Adult)===
 
====Guideline-Supported Use====
 
=====Condition 1=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information
 
:: (Dosage)
 
=====Condition 2=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information
 
:: (Dosage)
 
====Non–Guideline-Supported Use====
 
=====Condition 1=====
 
* Dosing Information
 
:: (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:: (Dosage)
 
=====Condition 3=====
 
* Dosing Information
 
:: (Dosage)
 
==Pediatric Indications and Dosage==
 
===FDA-Labeled Indications and Dosage (Pediatric)===
 
=====Condition 1=====
 
* Dosing Information
 
:: (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:: (Dosage)
 
===Off-Label Use and Dosage (Pediatric)===
 
====Guideline-Supported Use====
 
=====Condition 1=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information
 
:: (Dosage)
 
=====Condition 2=====
 
* Developed by: (Organisation)
 
* Class of Recommendation: (Class) (Link)
 
* Strength of Evidence: (Category A/B/C) (Link)
 
* Dosing Information
 
:: (Dosage)
 
====Non–Guideline-Supported Use====
 
=====Condition 1=====
 
* Dosing Information
 
:: (Dosage)
 
=====Condition 2=====
 
* Dosing Information
 
:: (Dosage)
 
=====Condition 3=====
 
* Dosing Information
 
:: (Dosage)
 
==Contraindications==
 
* Condition 1
* Condition 2
* Condition 3
* Condition 4
* Condition 5
 
==Warnings==
 
=====Conidition 1=====
 
(Description)
 
=====Conidition 2=====
 
(Description)
 
=====Conidition 3=====
 
(Description)
 
==Adverse Reactions==
 
===Clinical Trials Experience===
 
=====Condition 1=====
 
======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
 
=====Condition 1=====
 
======Central Nervous System======
 
: (list/description of adverse reactions)
 
======Cardiovascular======
 
: (list/description of adverse reactions)
 
======Respiratory======
 
: (list/description of adverse reactions)
 
======Gastrointestinal======
 
: (list/description of adverse reactions)
 
======Hypersensitive Reactions======
 
: (list/description of adverse reactions)
 
======Miscellaneous======
 
: (list/description of adverse reactions)
 
===Postmarketing Experience===
 
(Description)
 
==Drug Interactions==
 
* Drug 1
* Drug 2
* Drug 3
* Drug 4
* Drug 5
 
=====Drug 1=====
 
(Description)
 
=====Drug 2=====
 
(Description)
 
=====Drug 3=====
 
(Description)
 
=====Drug 4=====
 
(Description)
 
=====Drug 5=====
 
(Description)
 
==Use in Specific Populations==
 
====Pregnancy====
 
: '''[[Pregnancy category#United States|Pregnancy Category (FDA)]]: X'''
 
: '''[[Pregnancy category#Australia|Pregnancy Category (AUS)]]: X'''
 
(Description)
 
====Labor and Delivery====
 
(Description)
 
====Nursing Mothers====
 
(Description)
 
====Pediatric Use====
 
(Description)
 
====Geriatric Use====
 
(Description)
 
====Gender====
 
(Description)
 
====Race====
 
(Description)
 
====Renal Impairment====
 
(Description)
 
====Hepatic Impairment====
 
(Description)
 
====Females of Reproductive Potential and Males====
 
(Description)
 
====Immunocompromised Patients====
 
(Description)
 
==Administration and Monitoring==
 
====Administration====
 
(Oral/Intravenous/etc)
 
====Monitoring====
 
=====Condition 1=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 2=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
=====Condition 3=====
 
(Description regarding monitoring, from ''Warnings'' section)
 
==IV Compatibility==
 
===Solution===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Y-Site===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Admixture===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===Syringe===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
===TPN/TNA===
 
====Compatible====
 
* Solution 1
* Solution 2
* Solution 3
 
====Not Tested====
 
* Solution 1
* Solution 2
* Solution 3
 
====Variable====
 
* Solution 1
* Solution 2
* Solution 3
 
====Incompatible====
 
* Solution 1
* Solution 2
* Solution 3
 
==Overdosage==
 
===Acute Overdose===
 
====Signs and Symptoms====
 
(Description)
 
====Management====
 
(Description)
 
===Chronic Overdose===
 
====Signs and Symptoms====
 
(Description)
 
====Management====
 
(Description)
 
==Pharmacology==
 
{{Drugbox2
| verifiedrevid =
| IUPAC_name =
| image =
| drug_name =
 
<!--Clinical data-->
| tradename =
| MedlinePlus =
| licence_US =
| pregnancy_AU =
| pregnancy_US =
| legal_status =
| routes_of_administration =
 
<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =
 
<!--Identifiers-->
| CAS_number_Ref =
| CAS_number =
| ATC_prefix =
| ATC_suffix =
| PubChem =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID =
| UNII_Ref =
| UNII =
| KEGG_Ref =
| KEGG =
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL =
 
<!--Chemical data-->
| C= | H= | N= | O=
| molecular_weight =
| smiles =
| InChI =
| InChIKey =
| StdInChI_Ref =
| StdInChI =
| StdInChIKey_Ref =
| StdInChIKey =
| melting_point =
}}
}}
{{DrugProjectForm
|hasBlackBoxWarning=Yes
|blackBoxWarningTitle=WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
|blackBoxWarningBody=A. BLEEDING RISK


* BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.
===Mechanism of Action===
* Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage.
* Do not start BRILINTA in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at least 5 days prior to any surgery.
* Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of BRILINTA.
* If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events.


B. ASPIRIN DOSE AND BRILINTA EFFECTIVENESS
(Description)


Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. After any initial dose, use with aspirin 75-100 mg per day.
===Structure===
|fdaLIADAdult=Acute Coronary Syndromes


BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent thrombosis [see Clinical Studies (14)].
(Description with picture)


BRILINTA has been studied in ACS in combination with aspirin. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of aspirin above 100 mg daily [see Warnings and Precautions (5.2) and Clinical Studies (14)].
===Pharmacodynamics===
|warnings=5.1 General Risk of Bleeding


Drugs that inhibit platelet function including BRILINTA increase the risk of bleeding. BRILINTA increased the overall risk of bleeding (Major + Minor) to a somewhat greater extent than did clopidogrel. The increase was seen for non-CABG-related bleeding, but not for CABG-related bleeding. Fatal and life-threatening bleeding rates were not increased [see Adverse Reactions (6.1)].
(Description)


In general, risk factors for bleeding include older age, a history of bleeding disorders, performance of percutaneous invasive procedures, and concomitant use of medications that increase the risk of bleeding (e.g., anticoagulant and fibrinolytic therapy, higher doses of aspirin, and chronic nonsteroidal anti-inflammatory drugs [NSAIDS]).
===Pharmacokinetics===


When possible, discontinue BRILINTA five days prior to surgery. Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, PCI, CABG, or other surgical procedures, even if the patient does not have any signs of bleeding.
(Description)


If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events [see Warnings and Precautions (5.5) and Adverse Reactions (6.1)].
===Nonclinical Toxicology===


5.2 Concomitant Aspirin Maintenance Dose
(Description)


In PLATO, use of BRILINTA with maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Therefore, after the initial loading dose of aspirin (usually 325 mg), use BRILINTA with a maintenance dose of aspirin of 75-100 mg [see Dosage and Administration (2) and Clinical Studies (14)].
==Clinical Studies==


5.3 Moderate Hepatic Impairment
=====Condition 1=====


BRILINTA has not been studied in patients with moderate hepatic impairment. Consider the risks and benefits of treatment, noting the probable increase in exposure to ticagrelor.
(Description)


5.4 Dyspnea
=====Condition 2=====


In PLATO, dyspnea was reported in 14% of patients treated with BRILINTA and in 8% of patients taking clopidogrel. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment, but occasionally required discontinuation (0.9% of patients taking BRILINTA versus 0.1% of patients taking clopidogrel). If a patient develops new, prolonged, or worsened dyspnea during treatment with BRILINTA, exclude underlying diseases that may require treatment. If dyspnea is determined to be related to BRILINTA, no specific treatment is required; continue BRILINTA without interruption. In the case of intolerable dyspnea requiring discontinuation of BRILINTA, consider prescribing another antiplatelet agent.
(Description)


In a substudy, 199 patients from PLATO underwent pulmonary function testing irrespective of whether they reported dyspnea. There was no significant difference between treatment groups for FEV1. There was no indication of an adverse effect on pulmonary function assessed after one month or after at least 6 months of chronic treatment.
=====Condition 3=====


5.5 Discontinuation of BRILINTA
(Description)


Avoid interruption of BRILINTA treatment. If BRILINTA must be temporarily discontinued (e.g., to treat bleeding or for elective surgery), restart it as soon as possible. Discontinuation of BRILINTA will increase the risk of myocardial infarction, stent thrombosis, and death.
==How Supplied==


5.6 Strong Inhibitors of Cytochrome CYP3A
(Description)


Ticagrelor is metabolized by CYP3A4/5. Avoid use with strong CYP3A inhibitors, such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
* National Drug Code (NDC):
* Storage:
* Manufactured by: 
* Distributed by:


5.7 Cytochrome CYP3A Potent Inducers
==Images==


Avoid use with potent CYP3A inducers, such as rifampin, dexamethasone, phenytoin, carbamazepine, and phenobarbital [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].
===Drug Images===


|hasUsageInfo=In Progress
(PillBox Images)
}}
 
===Package and Label Display Panel===
 
(Package Images)
 
(Display Panel Images)
 
==Patient Information==
 
===Patient Information from FDA===
 
(Patient Counseling Information)
 
===Patient Information from NLM===
 
(Link to patient information page)
 
==Precautions with Alcohol==
 
Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
==Look-Alike Drug Names==
 
* (Paired Confused Name 1a) — (Paired Confused Name 1b)
* (Paired Confused Name 2a) — (Paired Confused Name 2b)
* (Paired Confused Name 3a) — (Paired Confused Name 3b)
 
==[http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792.htm Drug Shortage Status]==
 
==[http://www.goodrx.com/{{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}/price Price]==
 
==References==
 
{{reflist}}
 
</div>

Latest revision as of 19:42, 28 March 2014

Brilinta tablet®
Black Box Warning
Adult Indications and Dosage
Pediatric Indications and Dosage
Contraindications
Warnings
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration and Monitoring
IV Compatibility
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient information
Precautions with Alcohol
Brand Names
Look-Alike Drug Names
Drug Shortage Status
Price

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

For information about (Ticagrelor), click here.

Disclaimer

WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature. The information provided is not a medical advice or treatment. WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer here.

Black Box Warning

WARNING: (A) BLEEDING RISK, and (B) ASPIRIN DOSE AND Brilinta EFFECTIVENESS

See full prescribing information for complete boxed warning.

BLEEDING RISK:

  • Brilinta, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.
  • Do not use Brilinta in patients with active pathological bleeding or a history of intracranial hemorrhage.
  • Do not start Brilinta in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Brilinta at least 5 days prior to any surgery.
  • Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgery.
  • If possible, manage bleeding without discontinuing Brilinta. Stopping Brilinta increases the risk of subsequent cardiovascular events.

ASPIRIN DOSE AND Brilinta EFFECTIVENESS:

  • Maintenance doses of aspirin above 100 mg reduce the effectiveness of Brilinta and should be avoided.

Overview

Brilinta tablet is a P2Y12 platelet inhibitor and platelet aggregation inhibitor drug that is FDA approved for the treatment of acute coronary syndromes (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). There is a Black Box Warning for this drug as shown here. Common adverse reactions include _______.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Acute Coronary Syndromes

  • Dosing Information
Brilinta tablet 180 mg tablet PO (two 90 mg tablets) loading dose and then continue treatment with 90 mg twice daily.
After the initial loading dose of aspirin (usually 325 mg), use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg.
ACS patients who have received a loading dose of clopidogrel may be started on BRILINTA.
BRILINTA can be administered with or without food.
A patient who misses a dose of BRILINTA should take one 90 mg tablet (their next dose) at its scheduled time.


Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information
(Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information
(Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
(Dosage)
Condition 2
  • Dosing Information
(Dosage)
Condition 3
  • Dosing Information
(Dosage)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition 1
  • Dosing Information
(Dosage)
Condition 2
  • Dosing Information
(Dosage)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition 1
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information
(Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information
(Dosage)

Non–Guideline-Supported Use

Condition 1
  • Dosing Information
(Dosage)
Condition 2
  • Dosing Information
(Dosage)
Condition 3
  • Dosing Information
(Dosage)

Contraindications

  • Condition 1
  • Condition 2
  • Condition 3
  • Condition 4
  • Condition 5

Warnings

Conidition 1

(Description)

Conidition 2

(Description)

Conidition 3

(Description)

Adverse Reactions

Clinical Trials Experience

Condition 1
Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)
Condition 1
Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)

Postmarketing Experience

(Description)

Drug Interactions

  • Drug 1
  • Drug 2
  • Drug 3
  • Drug 4
  • Drug 5
Drug 1

(Description)

Drug 2

(Description)

Drug 3

(Description)

Drug 4

(Description)

Drug 5

(Description)

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): X
Pregnancy Category (AUS): X

(Description)

Labor and Delivery

(Description)

Nursing Mothers

(Description)

Pediatric Use

(Description)

Geriatric Use

(Description)

Gender

(Description)

Race

(Description)

Renal Impairment

(Description)

Hepatic Impairment

(Description)

Females of Reproductive Potential and Males

(Description)

Immunocompromised Patients

(Description)

Administration and Monitoring

Administration

(Oral/Intravenous/etc)

Monitoring

Condition 1

(Description regarding monitoring, from Warnings section)

Condition 2

(Description regarding monitoring, from Warnings section)

Condition 3

(Description regarding monitoring, from Warnings section)

IV Compatibility

Solution

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Y-Site

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Admixture

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Syringe

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

TPN/TNA

Compatible

  • Solution 1
  • Solution 2
  • Solution 3

Not Tested

  • Solution 1
  • Solution 2
  • Solution 3

Variable

  • Solution 1
  • Solution 2
  • Solution 3

Incompatible

  • Solution 1
  • Solution 2
  • Solution 3

Overdosage

Acute Overdose

Signs and Symptoms

(Description)

Management

(Description)

Chronic Overdose

Signs and Symptoms

(Description)

Management

(Description)

Pharmacology

Brilinta tablet
Systematic (IUPAC) name
?
Identifiers
CAS number ?
ATC code ?
PubChem ?
Chemical data
Formula ?
Mol. mass ?
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes ?

Mechanism of Action

(Description)

Structure

(Description with picture)

Pharmacodynamics

(Description)

Pharmacokinetics

(Description)

Nonclinical Toxicology

(Description)

Clinical Studies

Condition 1

(Description)

Condition 2

(Description)

Condition 3

(Description)

How Supplied

(Description)

  • National Drug Code (NDC):
  • Storage:
  • Manufactured by:
  • Distributed by:

Images

Drug Images

(PillBox Images)

Package and Label Display Panel

(Package Images)

(Display Panel Images)

Patient Information

Patient Information from FDA

(Patient Counseling Information)

Patient Information from NLM

(Link to patient information page)

Precautions with Alcohol

Alcohol-Brilinta tablet interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Look-Alike Drug Names

  • (Paired Confused Name 1a) — (Paired Confused Name 1b)
  • (Paired Confused Name 2a) — (Paired Confused Name 2b)
  • (Paired Confused Name 3a) — (Paired Confused Name 3b)

Drug Shortage Status

Price

References

Retrieved from "https://www.wikidoc.org/index.php?title=Brilinta_tablet&oldid=960896"